AR-V7 protein in circulating tumor cells is a predictive marker of shorter progression-free and overall survival with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer.
Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.
Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.
An application has been submitted to Japan's Ministry of Health, Labor and Welfare for darolutamide for the treatment of patients with castration-resistant prostate cancer.
Raoul S. Concepcion, MD, FACS, discusses the clinical implications of the findings from the ARAMIS trial and highlights other therapies that are coming down the pike for the treatment of patients with castration-resistant prostate cancer.
Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.
A new drug application has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Sumit K. Subudhi, MD, PhD, discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castration-resistant prostate cancer and the challenges that lie ahead with this treatment approach.
Benjamin A. Gartrell, MD, discusses the promise of SM-88 in this patient population, as well as other therapeutic options that are emerging for various prostate cancer subtypes.
It may take a restructuring of our current practice models, but we need to embrace, understand, and incorporate new technologies, both surgical and nonsurgical, to be at the forefront of precision medicine for our patients.